AORT Stock Overview
Manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AORT from our risk checks.
Artivion, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$25.40 |
52 Week High | US$29.24 |
52 Week Low | US$12.16 |
Beta | 1.75 |
11 Month Change | 0.51% |
3 Month Change | 9.01% |
1 Year Change | 51.28% |
33 Year Change | -4.98% |
5 Year Change | -2.68% |
Change since IPO | 535.00% |
Recent News & Updates
Is Artivion (NYSE:AORT) A Risky Investment?
Jun 28Data-Driven Growth Fuels More Upside For Overlooked Artivion
Jun 21Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 08Recent updates
Is Artivion (NYSE:AORT) A Risky Investment?
Jun 28Data-Driven Growth Fuels More Upside For Overlooked Artivion
Jun 21Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 08Is Artivion (NYSE:AORT) Using Too Much Debt?
Jan 13Artivion Stock: A First Assessment
Dec 27Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump
Nov 23Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025
Oct 13Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
Jul 20Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M
Feb 16Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold
Dec 18Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Sep 27Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M
Aug 04Is Artivion (NYSE:AORT) Using Too Much Debt?
Jun 27Is Artivion (NYSE:AORT) Using Too Much Debt?
Mar 25CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet
Dec 08Shareholder Returns
AORT | US Medical Equipment | US Market | |
---|---|---|---|
7D | -6.7% | -1.3% | -5.6% |
1Y | 51.3% | -0.7% | 12.4% |
Return vs Industry: AORT exceeded the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: AORT exceeded the US Market which returned 12.4% over the past year.
Price Volatility
AORT volatility | |
---|---|
AORT Average Weekly Movement | 4.9% |
Medical Equipment Industry Average Movement | 8.4% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.6% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AORT has not had significant price volatility in the past 3 months.
Volatility Over Time: AORT's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 1,500 | Pat Mackin | artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
Artivion, Inc. Fundamentals Summary
AORT fundamental statistics | |
---|---|
Market cap | US$1.04b |
Earnings (TTM) | -US$9.58m |
Revenue (TTM) | US$368.21m |
2.9x
P/S Ratio-110.6x
P/E RatioIs AORT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AORT income statement (TTM) | |
---|---|
Revenue | US$368.21m |
Cost of Revenue | US$129.81m |
Gross Profit | US$238.40m |
Other Expenses | US$247.98m |
Earnings | -US$9.58m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | -0.23 |
Gross Margin | 64.74% |
Net Profit Margin | -2.60% |
Debt/Equity Ratio | 106.2% |
How did AORT perform over the long term?
See historical performance and comparison